ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.

doi:10.1016/j.canep.2015.12.012

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.

Cancer epidemiology - 1 Apr 2016

Cuffe Sinead, Azad Abul Kalam, Qiu Xiaoping, Qiu Xin, Brhane Yonathan, Kuang Qin, Marsh Sharon, Savas Sevtap, Chen Zhuo, Cheng Dangxiao, Leighl Natasha B, Goss Glenwood, Laurie Scott A, Seymour Lesley, Bradbury Penelope A, Shepherd Frances A, Tsao Ming Sound, Chen Bingshu E, Xu Wei, Liu Geoffrey

Abstract excerpt

BACKGROUND: The drug transporter ABCC2 is upregulated in non-small cell lung cancer (NSCLC) and implicated in platinum resistance. We evaluated the association between germline polymorphisms in the ABCC2 gene and survival outcomes of platinum-treated advanced NSCLC patients. MATERIAL AND METHODS: Ten candidate and tagging germline polymorphisms in the ABCC2 gene were genotyped in a discovery cohort of 170...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Lung Neoplasms

Share to Multidrug Resistance-Associated Protein 2

Share to Multidrug Resistance-Associated Proteins

Share to Prognosis

Share to Proportional Hazards Models

Share to Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 26816351
DOI: 10.1016/j.canep.2015.12.012

Genes

ABCC2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.PMID 26816351Read ↗

Genetic Variants Associated With Response to Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer Patients: A Field Synopsis and Meta-Analysis.Semantic proximity Read ↗

Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.Semantic proximity Read ↗

A pharmacogenetics study of platinum-based chemotherapy in lung cancer: ABCG2 polymorphism and its genetic interaction with SLC31A1 are associated with response and survivalSemantic proximity Read ↗

Impact of ABCB1, ABCC1, ABCC2, and ABCG2 variants in predicting prognosis and clinical outcomes of north Indian lung cancer patients undergoing platinum-based doublet chemotherapy.Semantic proximity Read ↗

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.Semantic proximity Read ↗

Genome-wide association study of prognosis in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy.Semantic proximity Read ↗

Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non-Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy.Semantic proximity Read ↗

Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients.Semantic proximity Read ↗

Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.Semantic proximity Read ↗

The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients.Semantic proximity Read ↗

Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.